Literature DB >> 33082245

Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy.

Kieran F Docherty1, Pardeep S Jhund1, Olof Bengtsson2, David L DeMets3, Silvio E Inzucchi4, Lars Køber5, Mikhail N Kosiborod6,7, Anna Maria Langkilde2, Felipe A Martinez8, Marc S Sabatine9, Mikaela Sjöstrand2, Scott D Solomon10, John J V McMurray.   

Abstract

OBJECTIVE: To determine whether the benefits of dapagliflozin in patients with heart failure and reduced ejection fraction (HFrEF) and type 2 diabetes in the Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure trial (DAPA-HF) varied by background glucose-lowering therapy (GLT). RESEARCH DESIGN AND METHODS: We examined the effect of study treatment by the use or not of GLT and by GLT classes and combinations. The primary outcome was a composite of worsening heart failure (hospitalization or urgent visit requiring intravenous therapy) or cardiovascular death.
RESULTS: In the 2,139 type 2 diabetes patients, the effect of dapagliflozin on the primary outcome was consistent by GLT use or no use (hazard ratio 0.72 [95% CI 0.58-0.88] vs. 0.86 [0.60-1.23]; interaction P = 0.39) and across GLT classes.
CONCLUSIONS: In DAPA-HF, dapagliflozin improved outcomes irrespective of use or no use of GLT or by GLT type used in patients with type 2 diabetes and HFrEF.
© 2020 by the American Diabetes Association.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33082245      PMCID： PMC7809714          DOI： 10.2337/dc20-1402

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


  13 in total

1.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.

Authors:  John J V McMurray; Scott D Solomon; Silvio E Inzucchi; Lars Køber; Mikhail N Kosiborod; Felipe A Martinez; Piotr Ponikowski; Marc S Sabatine; Inder S Anand; Jan Bělohlávek; Michael Böhm; Chern-En Chiang; Vijay K Chopra; Rudolf A de Boer; Akshay S Desai; Mirta Diez; Jaroslaw Drozdz; Andrej Dukát; Junbo Ge; Jonathan G Howlett; Tzvetana Katova; Masafumi Kitakaze; Charlotta E A Ljungman; Béla Merkely; Jose C Nicolau; Eileen O'Meara; Mark C Petrie; Pham N Vinh; Morten Schou; Sergey Tereshchenko; Subodh Verma; Claes Held; David L DeMets; Kieran F Docherty; Pardeep S Jhund; Olof Bengtsson; Mikaela Sjöstrand; Anna-Maria Langkilde
Journal:  N Engl J Med       Date:  2019-09-19       Impact factor: 91.245

2.  CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.

Authors:  Alan J Garber; Yehuda Handelsman; George Grunberger; Daniel Einhorn; Martin J Abrahamson; Joshua I Barzilay; Lawrence Blonde; Michael A Bush; Ralph A DeFronzo; Jeffrey R Garber; W Timothy Garvey; Irl B Hirsch; Paul S Jellinger; Janet B McGill; Jeffrey I Mechanick; Leigh Perreault; Paul D Rosenblit; Susan Samson; Guillermo E Umpierrez
Journal:  Endocr Pract       Date:  2020-01       Impact factor: 3.443

3.  Cardiorenal risk reduction guidance in diabetes: can we reach consensus?

Authors:  Naveed Sattar; John Jv McMurray; Alice Yy Cheng
Journal:  Lancet Diabetes Endocrinol       Date:  2020-03-11       Impact factor: 32.069

4.  SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

Authors:  Thomas A Zelniker; Stephen D Wiviott; Itamar Raz; Kyungah Im; Erica L Goodrich; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Remo H M Furtado; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Marc S Sabatine
Journal:  Lancet       Date:  2018-11-10       Impact factor: 79.321

Review 5.  2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.

Authors:  Francesco Cosentino; Peter J Grant; Victor Aboyans; Clifford J Bailey; Antonio Ceriello; Victoria Delgado; Massimo Federici; Gerasimos Filippatos; Diederick E Grobbee; Tina Birgitte Hansen; Heikki V Huikuri; Isabelle Johansson; Peter Jüni; Maddalena Lettino; Nikolaus Marx; Linda G Mellbin; Carl J Östgren; Bianca Rocca; Marco Roffi; Naveed Sattar; Petar M Seferović; Miguel Sousa-Uva; Paul Valensi; David C Wheeler
Journal:  Eur Heart J       Date:  2020-01-07       Impact factor: 29.983

6.  2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  John B Buse; Deborah J Wexler; Apostolos Tsapas; Peter Rossing; Geltrude Mingrone; Chantal Mathieu; David A D'Alessio; Melanie J Davies
Journal:  Diabetologia       Date:  2020-02       Impact factor: 10.122

7.  Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Melanie J Davies; David A D'Alessio; Judith Fradkin; Walter N Kernan; Chantal Mathieu; Geltrude Mingrone; Peter Rossing; Apostolos Tsapas; Deborah J Wexler; John B Buse
Journal:  Diabetologia       Date:  2018-12       Impact factor: 10.122

8.  Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.

Authors:  Mark C Petrie; Subodh Verma; Kieran F Docherty; Silvio E Inzucchi; Inder Anand; Jan Belohlávek; Michael Böhm; Chern-En Chiang; Vijay K Chopra; Rudolf A de Boer; Akshay S Desai; Mirta Diez; Jaroslaw Drozdz; Andre Dukát; Junbo Ge; Jonathan Howlett; Tzvetana Katova; Masafumi Kitakaze; Charlotta E A Ljungman; Béla Merkely; Jose C Nicolau; Eileen O'Meara; Pham Nguyen Vinh; Morten Schou; Sergey Tereshchenko; Lars Køber; Mikhail N Kosiborod; Anna Maria Langkilde; Felipe A Martinez; Piotr Ponikowski; Marc S Sabatine; Mikaela Sjöstrand; Scott D Solomon; Per Johanson; Peter J Greasley; David Boulton; Olof Bengtsson; Pardeep S Jhund; John J V McMurray
Journal:  JAMA       Date:  2020-04-14       Impact factor: 56.272

9.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur Heart J       Date:  2016-05-20       Impact factor: 29.983

10.  A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).

Authors:  John J V McMurray; David L DeMets; Silvio E Inzucchi; Lars Køber; Mikhail N Kosiborod; Anna M Langkilde; Felipe A Martinez; Olof Bengtsson; Piotr Ponikowski; Marc S Sabatine; Mikaela Sjöstrand; Scott D Solomon
Journal:  Eur J Heart Fail       Date:  2019-03-21       Impact factor: 15.534
View more
  3 in total

1.  Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes.

Authors:  Brendon L Neuen; Clare Arnott; Vlado Perkovic; Gemma Figtree; Dick de Zeeuw; Greg Fulcher; Min Jun; Meg J Jardine; Sophia Zoungas; Carol Pollock; Kenneth W Mahaffey; Bruce Neal; Hiddo J L Heerspink
Journal:  Diabetes Obes Metab       Date:  2020-10-29       Impact factor: 6.577

Review 2.  Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction.

Authors:  Hannah A Blair
Journal:  Am J Cardiovasc Drugs       Date:  2021-10-15       Impact factor: 3.571

3.  Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents.

Authors:  Atsushi Tanaka; Shigeru Toyoda; Takumi Imai; Kazuki Shiina; Hirofumi Tomiyama; Yasushi Matsuzawa; Takahiro Okumura; Yumiko Kanzaki; Katsuya Onishi; Arihiro Kiyosue; Masami Nishino; Yasushi Sakata; Koichi Node
Journal:  Cardiovasc Diabetol       Date:  2021-09-03       Impact factor: 9.951
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.